. 2014 Dec 8;9:5711–5727. doi: 10.2147/IJN.S74353

Table 1.

Characterization of LHSA-based nanoparticles

Formulation	Particle size (nm)	Polydispersity index	Zeta potential (mV)	Encapsulation efficiency (%)	Drug loading content (%)	CMC (mg/mL)	Factor Xa (%)
LHSA1	146.10±8.92	0.25±0.07	−15.39±8.44	–	–	ND	60.41
LHSA3	175.60±6.54	0.23±0.08	−33.92±1.34	–	–	ND	32.09
LHSA5	177.90±7.22	0.17±0.04	−33.13±0.72	–	–	0.044	31.92
LHSA5/DCT (5:1, w/w)	155.20±3.46	0.16±0.04	−35.34±0.26	59.82±3.86	10.68±0.61	–	33.48

Notes:

$\begin{array}{l} Encapsulation efficiency (%) = \frac{Actual amount of docetaxel in formulation}{Input amount of docetaxel in formulation} \times 100. \\ Drug loading content (%) = \frac{Amount of docetaxel in formulation (mg)}{Amount of formulation (mg)} \times 100. \end{array}$

Abbreviations: CMC, critical micelle concentration; ND, not determined.